frogmister

Dendreon: The FDA's Commissioner Doth Protest Too Much!

Been There...here's the data you requested. Note the historical data supports the last group's survival numbers, which are small samples. For those not familiar with the trials, patients had the option to "crossover" to recieve chemo upon progression.

Provenge PIII 36 month survival data:

Provenge Arm 9901: 28/82 = 34.1%
Provenge Arm 9902A: 21/65 = 32.3%
Provenge Arm Pooled: 49/147 = 33.3%

Placebo Arm 9901: 5/45 = 11.1%
Placebo Arm 9902A: 7/33 = 21.2%
Placebo Arm Pooled: 12/78 = 15.4%

Placebo Arm Crossovers 9901: 4/34 = 11.8%
Placebo Arm Crossovers 9902A: 6/24 = 25% or 6/25 = 24%
Placebo Arm Crossovers Pooled: 10/58 = 17.2% or 10/59 = 16.9%

Placebo Arm Non-Crossovers 9901: 1/11 = 9.1%
Placebo Arm Non-Crossovers 9902A: 1/8 = 12.5% or 1/9 = 11.1%
Placebo Arm Non-Crossovers Pooled: 2/19 = 10.5% or 2/20 = 10%